Khedezla FDA Approval History
FDA Approved: Yes (First approved July 10, 2013)
Brand name: Khedezla
Generic name: desvenlafaxine
Dosage form: Extended-Release Tablets
Company: Osmotica Pharmaceutical Corp.
Treatment for: Depression
Khedezla (desvenlafaxine) is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder.
Development timeline for Khedezla
| Date | Article |
|---|---|
| Jul 11, 2013 | Approval FDA Approves Khedezla for Major Depressive Disorder |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
